Strategic Acquisition Zeovacor is now part of a broader platform under Curium following a June 2024 acquisition, presenting a pathway to access their radiopharmaceutical portfolio, distribution networks, and customer base for cross-sell opportunities in PET and SPECT imaging products and services.

Integrated Capabilities The company develops and distributes radiopharmaceuticals and provides educational services, plus investigative and custom radiolabeling capabilities, enabling a comprehensive offering that can be upsold with imaging education, research collaboration, and turnkey radiolabeling services to pharma and biotech clients.

Nuclear Medicine Focus With a 70 MeV cyclotron project and multiple synthesis units in Noblesville, IN, Zevacor is expanding production capacity for clinical and research radioisotopes, creating opportunities to offer enhanced supply reliability, faster lead times, and custom radiochemistry solutions to imaging trials.

Nonprofit Backing As part of Illinois Health and Science, Zevacor operates within a mission-driven health system, which can be leveraged to position premium partnerships around patient outcomes, cost-effective imaging workflows, and potential grant-supported collaborations with healthcare institutions.

Market Position & Scale Compared to benchmark peers in large medtech groups, Zevacor’s revenue range and mid-market staff size indicate a nimble, specialist partner ideal for targeted engagements in radiopharmaceutical development, radiolabeling services, and value-added education for clinical trials and academia.